Evaluation of Short-term Outcomes of Ambulatory Loop Ileostomy Reversal

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05552170

Enrollment

216

Registered

2022-09-23

Start date

2017-08-01

Completion date

2025-08-31

Last updated

2022-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fast Recovery Surgery, Surgery

Brief summary

Based on enhanced recovery after surgery (ERAS), ambulatory loop ileostomy reversal (ALIR) has been reported in developed countries. However, there is still no research proposing how to carry out ALIR in developing countries. This study was performed to determine the feasibility of ALIR in China based on the community hospital joined enhanced recovery after surgery (CHJ-ERAS) program.

Detailed description

CHJ-ERAS program for ALIR was launched. Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation. Strict follow-ups were conducted after ALIR. The primary outcome was the results of short-term follow-ups.

Interventions

OTHERday-case surgery

Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. Patients with ileostoma and preparing for LIR 2. Patients age between 18-65; 3. ASA grade II; 4. Patients willing to underwent day-case LIR

Exclusion criteria

* 1\) Patients who underwent single-lumen ileostomy, transverse colostomy or Hartmann; 2) Complex previous laparotomies or required exploratory laparotomy; 3) Age over 65; 4) ASA grade over III (assessed by anesthetists); 5) Presence of moderate or severe preoperative anemia (hemoglobin \<90g/L); 6) Therapeutic anticoagulation or anti-platelet medications used within 1 week before surgery; 7) Patient refusal; 8) Severe co-morbidities or other conditions evaluated by surgeons or anesthetists not inappropriate to be included in the program.

Design outcomes

Primary

Measure	Time frame	Description
Results of short-term follow-up	Within 1 month after surgery	The occurrence of postoperative complications
Readmissions	Within 1 month after surgery	Readmission within 1 month after surgery
Reoperation	Within 1 month after surgery	Reoperation within 1 month after surgery

Secondary

Measure	Time frame	Description
Hospital stays	1 day	Hospital stays

Countries

China

Contacts

Primary ContactZiqiang Wang, PHD

wangziqiang@scu.edu.cn+8618980602028

Backup ContactYu Shen, MD

hi_moke@163.com+8617606441760

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026